临床试验/IRCT20210519051345N6

IRCT20210519051345N6招募中未知

Fasted state in vivo bioequivalence study for Imatinib 100 mg capsule manufactured by Avicenna Co. in comparison to German brand AQVIDA

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2021年11月29日

试验速览

阶段: 未知
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20 years 至 60 years（—）
性别: All

入选标准

•General Health including Liver, Heart and Kidney health
•Being at the age of 25-55 years old

排除标准

•History of cardiovascular disease
•History of liver and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence study of Famotidine 40 mg tablet.

IRCT20210519051345N39Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Famotidine tablet

IRCT20220211053992N35Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Azithromycin tablet

IRCT20220211053992N37Tabriz University of Medical Sciences24

Investigating the in vivo bioequivalence of Lamotrigine 100 mg

IRCT20210519051345N41Tabriz University of Medical Sciences24

Investigating the in vivo bioequivalence of Escitalopram 20 mg tabletIn the present study, the products will be administered to healthy volunteers.

IRCT20210519051345N55Tabriz University of Medical Sciences24

In vivo bioequivalence study of Imatinib 100 mg... | 临床试验